As of 24 September 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of alendronic acid (as sodium alendronate) 70 mg effervescent tablet for the treatment of postmenopausal osteoporosis. The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from 24 September to 07 October 2026.

As a preliminary recommendation, the HTA Council conditionally recommends the government financing of alendronic acid (as sodium alendronate) 70 mg effervescent tablet only if its price is reduced to a level that is competitive with the PNF-listed alendronate 70 mg tablet through price negotiation.

For the supporting evidence reviewed and discussed by the HTA Council, please refer to the document below.

All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 07 October 2026 (Wednesday) using the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format, and those submitted beyond the deadline, shall not be entertained.